EUVIMEDScopri EUVIMED
CrossrefScheda informativa

Exploring Weight Loss Medication Discourse: Mixed Methods Analysis of US-Based Facebook Posts

Elizabeth Dennard, Katrina Makres, Amrutha Alibilli, Vidur Jain, Anne Wang, Roger Abim-Karmon, Shaniece Criss, Yulin Hswen, Quynh C Nguyen, Alexandria Ratzki-Leewing, Rozalina G McCoy, Thu T Nguyen

JMIR Infodemiology · 2026-05-07 · 6 · e89732-e89732

DOI: 10.2196/89732 ↗
AbstractDati bibliografici

Abstract

Abstract Background Despite the documented clinical efficacy of weight loss medications, few large-scale mixed methods studies have captured the experiences of individuals taking these medications. Objective This study aims to examine dominant themes and public narratives about the perceived benefits, challenges, identity-based experiences, and the broader sociocultural framing of glucagon-like peptide-1 receptor agonist use on Facebook. Methods We used CrowdTangle to collect 2500 US-based Facebook posts from January 1, 2022, to May 31, 2024. Bidirectional encoder representations from transformers topic modeling was used to identify latent topics, followed by a qualitative thematic analysis. Results An analysis of 2500 Facebook posts revealed distinct thematic patterns across five unique subcategories: (1) healthy weight management, (2) weight loss medications, (3) discussion specific to semaglutide, (4) discussions specific to Ozempic, and (5) public figures and media. Thirteen overarching themes emerged through this thematic analysis, with the most common themes including weight management programs (n=702), neutral content related to weight loss medication use (n=466), harms of weight loss medication use (n=373), benefits of weight loss medication use (n=329), and access to these medications (n=188). Conclusions Social media provides critical insights into individual experiences with pharmacotherapy and weight management. Enhanced public education may optimize the safe use of glucagon-like peptide-1 receptor agonists for weight loss.

Conoscenze adatte al tuo lavoro.

Dall’inizio gratuito alla ricerca bibliografica personale, fino alla Research Suite completa.

Visualizza tariffe →

Sono inclusi tutti i testi integrali degli editori?

No. Citazioni, abstract e testi integrali sono contenuti diversi. La disponibilità dipende dalla fonte, dall’accesso aperto e dalle licenze esistenti. Un piano EUVIMED non sostituisce diritti aggiuntivi degli editori.

Visualizza tariffe →